Results 171 to 180 of about 30,729 (226)
Some of the next articles are maybe not open access.
Related searches:
Related searches:
American Journal of Psychiatry, 2022
OBJECTIVE Altered glutamatergic neurotransmission is implicated in the pathogenesis of major depressive disorder. AXS-05 (dextromethorphan-bupropion) is an oral NMDA receptor antagonist and sigma-1 receptor agonist, which utilizes inhibition of CYP2D6 to
Dan V Iosifescu +2 more
exaly +2 more sources
OBJECTIVE Altered glutamatergic neurotransmission is implicated in the pathogenesis of major depressive disorder. AXS-05 (dextromethorphan-bupropion) is an oral NMDA receptor antagonist and sigma-1 receptor agonist, which utilizes inhibition of CYP2D6 to
Dan V Iosifescu +2 more
exaly +2 more sources
American Journal of Psychiatry, 2022
Objective: Binge-eating disorder (BED), the most prevalent eating disorder, is a serious public health problem associated with obesity, psychiatric/medical comorbidities, and functional impairments.
C. Grilo +5 more
semanticscholar +1 more source
Objective: Binge-eating disorder (BED), the most prevalent eating disorder, is a serious public health problem associated with obesity, psychiatric/medical comorbidities, and functional impairments.
C. Grilo +5 more
semanticscholar +1 more source
Drug Intelligence & Clinical Pharmacy, 1984
Bupropion is a trimethylated monocyclic phenylaminoketone that is an effective antidepressant in humans. It neither is sedating, anticholinergic, nor cardiotoxic. Its mechanism of action may be related to dopamine, but remains uncertain at this time. Clinical trials comparing bupropion 300–750 mg/d with placebo show it to be superior ...
Dufresne, R., Weber, S., Becker, R. E.
openaire +3 more sources
Bupropion is a trimethylated monocyclic phenylaminoketone that is an effective antidepressant in humans. It neither is sedating, anticholinergic, nor cardiotoxic. Its mechanism of action may be related to dopamine, but remains uncertain at this time. Clinical trials comparing bupropion 300–750 mg/d with placebo show it to be superior ...
Dufresne, R., Weber, S., Becker, R. E.
openaire +3 more sources
Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant
Therapeutic Advances in Psychopharmacology, 2016 Bupropion has been used as an antidepressant for over 20 years, though its licence for such use varies and it is typically a third- or fourth-line agent.
David Baumeister +2 more
exaly +2 more sources
2016
Bupropion hydrochloride is a norepinephrine-dopamine disinhibitor (NDDI) approved for the treatment of depression and smoking cessation. Bupropion is a trimethylated monocyclic phenylaminoketone second-generation antidepressant, which differs structurally from most antidepressants, and resides in a novel mechanistic class that has no direct action on ...
S R, Khan +6 more
openaire +2 more sources
Bupropion hydrochloride is a norepinephrine-dopamine disinhibitor (NDDI) approved for the treatment of depression and smoking cessation. Bupropion is a trimethylated monocyclic phenylaminoketone second-generation antidepressant, which differs structurally from most antidepressants, and resides in a novel mechanistic class that has no direct action on ...
S R, Khan +6 more
openaire +2 more sources
Drugs of Today, 2006
Bupropion was initially developed and licensed for the treatment of major depressive disorder in the United States in 1989. It was licensed as a pharmacotherapy for smoking cessation in the United States in 1997 and in the United Kingdom in 2000, and for the prevention of seasonal major depressive episodes in patients with seasonal affective disorder ...
openaire +2 more sources
Bupropion was initially developed and licensed for the treatment of major depressive disorder in the United States in 1989. It was licensed as a pharmacotherapy for smoking cessation in the United States in 1997 and in the United Kingdom in 2000, and for the prevention of seasonal major depressive episodes in patients with seasonal affective disorder ...
openaire +2 more sources
Bupropion and Bupropion Analogs as Treatments for CNS Disorders
2014Bupropion, introduced as an antidepressant in the 1980s, is also effective as a smoking cessation aid and is beneficial in the treatment of methamphetamine addiction, cocaine dependence, addictive behaviors such as pathological gambling, and attention deficit hyperactivity disorder. (2S,3S)-hydroxybupropion is an active metabolite of bupropion produced
F Ivy, Carroll +5 more
openaire +2 more sources
A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder.
Psychopharmacology bulletinOBJECTIVE To compare the efficacy and safety of bupropion XL (150 to 300 mg/day) with the selective serotonin reuptake inhibitor escitalopram (10 to 20 mg/day) in outpatients diagnosed with generalized anxiety disorder (GAD).
A. Bystritsky +3 more
semanticscholar +1 more source